OCM
MRKR icon

Osterweis Capital Management’s Marker Therapeutics MRKR Stock Holding History

Osterweis Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,933
Closed -$945K – 116
2019
Q2 		$945K Buy
+11,933
New +$709K 0.07% 90

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Osterweis Capital Management's MRKR Position: Q3 2019 in Review

Osterweis Capital Management sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 11,933 shares — an estimated $945K sold.

Osterweis Capital Management first reported a position in MRKR in Q2 2019 and held it in 1 quarter. The position peaked at $945K in Q2 2019. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

  • Osterweis Capital Management reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Osterweis Capital Management sold 11,933 Marker Therapeutics shares in Q3 2019, an estimated $945K.
  • Osterweis Capital Management first reported a position in Marker Therapeutics in Q2 2019 and held it in 1 quarter.
  • Osterweis Capital Management's Marker Therapeutics position peaked at $945K in Q2 2019.
  • 73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on Osterweis Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.